Theravance Biopharma (NASDAQ:TPBH) reported new data from its Phase 2 trial of ampreloxetine in patients with neurogenic orthostatic hypotension (nOH).
nOH is characterized by a fall in systolic or diastolic blood pressure within three minutes of standing, which can result in cerebral hypoperfusion and syncope, or fainting.
Ampreloxetine is a norepinephrine reuptake inhibitor designed to correct the autonomic nervous system malfunction that causes nOH.
The new data demonstrated that, following four weeks of treatment, patients’ nOH symptoms improved, as did their ability to perform daily activities. Improvements were sustained until the end of 20 weeks of ampreloxetine therapy. After discontinuing treatment, patients’ symptoms worsened and their daily activity scores deteriorated, returning to baseline pre-treatment levels.
“Considering the significant unmet medical needs of nOH patients, we are working diligently to continue evaluation of the therapeutic potential of ampreloxetine through our ongoing placebo-controlled registrational Phase 3 program for the compound,” Dr. Brett Haumann, Theravance’s CMO, said in a statement.